HBC recorded total operating revenues of NOK 54.9 million in the third quarter of 2025, compared to NOK 67.9 million in the same period last year. Net operating revenues were NOK 54.8 million, reflecting lower commodity prices and a weaker U.S. dollar during the quarter. EBITDA for the quarter was NOK -21.1 million (-21.0) and the operational EBITDA* amounted to NOK -12.9 million (-13.9m), excluding non-recurring and strategic development costs such as clinical studies, R&D expenses, and Berkåk project cost ...